The Claim
Initiation of GLP-1 receptor agonists is associated with a reduced risk of substance use disorders across various demographic subgroups, including age (≤65 and >65), sex, race (white and black), BMI categories (≤30, 30–35, >35), HbA1c levels, and specific agents (semaglutide, liraglutide, dulaglutide), indicating that the observed association is consistent regardless of these patient characteristics.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Starting diabetes drugs like semaglutide or liraglutide might lower the chance of developing substance use problems, and this seems to be true for people of different ages, weights, races, and types of the drug.
See the scientific wording
The association between GLP-1 receptor agonist initiation and reduced risk of substance use disorders is consistent across different demographic subgroups including age (≤65 and >65), sex, race (white and black), BMI categories (≤30, 30-35, >35), HbA1c levels, and specific GLP-1 receptor agonist agents (semaglutide, liraglutide, dulaglutide), suggesting the effect is not limited to specific patient characteristics.
What the research says
1 studyThe study looked at people starting GLP-1 drugs like semaglutide and found they were less likely to develop substance use problems, and this was true for different ages, races, weights, and types of GLP-1 drugs.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.